Does Empagliflozin Linagliptin Metformin Hydrochloride Interact with Insulin Human?
Empagliflozin Linagliptin Metformin Hydrochloride and Insulin Human have a major drug interaction according to U.S. FDA drug labeling data. Concomitant use increases hypoglycemia risk; insulin dosage reduction may be needed. The mechanism involves additive hypoglycemic effects. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Empagliflozin Linagliptin Metformin Hydrochloride Class
- Dipeptidyl Peptidase 4 Inhibitor
- Insulin Human Class
- Insulin
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Empagliflozin Linagliptin Metformin Hydrochloride and Insulin Human occurs because additive hypoglycemic effects. Clinically, this means concomitant use increases hypoglycemia risk; insulin dosage reduction may be needed. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Empagliflozin Linagliptin Metformin Hydrochloride and your doctor is considering prescribing Insulin Human (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider